These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31872324)

  • 1. Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT.
    Majala S; Seppänen H; Kemppainen J; Sundström J; Schalin-Jäntti C; Gullichsen R; Schildt J; Mustonen H; Vesterinen T; Arola J; Kauhanen S
    EJNMMI Res; 2019 Dec; 9(1):116. PubMed ID: 31872324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Somatostatin Receptor 1-5 Expression, [
    Majala S; Vesterinen T; Seppänen H; Mustonen H; Sundström J; Schalin-Jäntti C; Gullichsen R; Schildt J; Kemppainen J; Arola J; Kauhanen S
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.
    Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.
    Zhou Z; Wang Z; Zhang B; Wu Y; Li G; Wang Z
    Front Endocrinol (Lausanne); 2021; 12():727327. PubMed ID: 34539577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors.
    Partelli S; Rinzivillo M; Maurizi A; Panzuto F; Salgarello M; Polenta V; Delle Fave G; Falconi M
    Neuroendocrinology; 2014; 100(4):293-9. PubMed ID: 25301162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis.
    Gormsen LC; Haraldsen A; Kramer S; Dias AH; Kim WY; Borghammer P
    EJNMMI Res; 2016 Dec; 6(1):52. PubMed ID: 27316444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of diagnostic efficacy of
    Zhang B; He Q; Long Y; Zhang Y; Wang X; Chen Z; Liu J; Zhang X
    Front Endocrinol (Lausanne); 2022; 13():962800. PubMed ID: 36213295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
    Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
    Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
    Calabrò D; Argalia G; Ambrosini V
    Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of a three-scale grading system based on combining molecular imaging with
    Karfis I; Marin G; Levillain H; Drisis S; Muteganya R; Critchi G; Taraji-Schiltz L; Guix CA; Shaza L; Elbachiri M; Mans L; Machiels G; Hendlisz A; Flamen P
    Oncotarget; 2020 Feb; 11(6):589-599. PubMed ID: 32110279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
    Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
    Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
    Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
    J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
    Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.